SCHEMBL31000883

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCC(=O)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	8/20	0.63

▸	ECE1	P42892	1/20	0.63

▸	MUS81	Q96NY9	1/20	0.63

▸	VIPR2	P41587	6/20	0.62

▸	VIPR1	P32241	4/20	0.61

▸	TFPI	P10646	1/20	0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30495597	0.91	VIPR2 (0.65)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL30429336	0.91	VIPR1 (0.65)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL30335650	0.90	GLP1R (0.63)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL30862330	0.90	GLP1R (0.62)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL31000926	0.90	GLP1R (0.65)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL31255179	0.89	VIPR2 (0.69)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL29867710	0.88	VIPR2 (0.61)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL30495613	0.88	VIPR1 (0.66)	GLP1RECE1MUS81VIPR2VIPR1
SCHEMBL30184264	0.88	TFPI (0.62)	TFPI
SCHEMBL31182890	0.88	TFPI (0.67)	GLP1RECE1MUS81VIPR2VIPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4630447-A2	ANTIBODIES OR FRAGMENTS THEREOF FOR SARS-COV-2 AND VARIANTS THEREOF	Abwiz Bio, Inc. (US)	2025-10-15	—	—	EP	disclosed
WO-2024124241-A2	ANTIBODIES OR FRAGMENTS THEREOF FOR SARS-COV-2 AND VARIANTS THEREOF	ABWIZ BIO, INC. (US)	2024-06-13	—	—	WO	disclosed